alendronate has been researched along with Autoimmune Diseases in 5 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Autoimmune Diseases: Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Subjects had just developed systemic autoimmune diseases and were randomized to be treated with 1 mg/kg/day prednisolone and alfacalcidol 1 microg/day alone (alfacalcidol group; n = 22), or prednisolone and alfacalcidol 1 microg/day with alendronate 5 mg/day (alendronate group; n = 25), each for 18 months." | 5.13 | Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy. ( Nakayamada, S; Nawata, M; Okada, Y; Saito, K; Tanaka, Y, 2008) |
| "Alendronate was the most frequently implicated (six cases) and risedronate (five cases)." | 1.36 | [Jaw osteonecrosis induced by oral biphosphonates: 12 cases]. ( Barrier, A; Descroix, V; Goudot, P; Lescaille, G; Rigolet, A; Ruhin, B, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Okada, Y | 1 |
| Nawata, M | 1 |
| Nakayamada, S | 1 |
| Saito, K | 1 |
| Tanaka, Y | 1 |
| Barrier, A | 1 |
| Lescaille, G | 1 |
| Rigolet, A | 1 |
| Descroix, V | 1 |
| Goudot, P | 1 |
| Ruhin, B | 1 |
| Tee, SI | 1 |
| Yosipovitch, G | 1 |
| Chan, YC | 1 |
| Chua, SH | 1 |
| Koh, ET | 1 |
| Chan, YH | 1 |
| Tan, SS | 1 |
| Tsou, IY | 1 |
| Tan, SH | 1 |
| Albrecht, J | 1 |
| Werth, VP | 1 |
| Takeda, S | 1 |
| Kaneoka, H | 1 |
| Saito, T | 1 |
3 trials available for alendronate and Autoimmune Diseases
| Article | Year |
|---|---|
Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy.
Topics: Adolescent; Adult; Alendronate; Autoimmune Diseases; Bone Density; Bone Density Conservation Agents; | 2008 |
Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study.
Topics: Administration, Oral; Adult; Alendronate; Anti-Inflammatory Agents; Autoimmune Diseases; Bone Densit | 2012 |
Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol.
Topics: Adult; Alendronate; Autoimmune Diseases; Biomarkers; Bone Density; Bone Density Conservation Agents; | 2008 |
2 other studies available for alendronate and Autoimmune Diseases
| Article | Year |
|---|---|
[Jaw osteonecrosis induced by oral biphosphonates: 12 cases].
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Alendronate; Autoimmu | 2010 |
Practice Gaps. Improving the care of our patients who are receiving glucocorticoid therapy.
Topics: Alendronate; Anti-Inflammatory Agents; Autoimmune Diseases; Bone Density Conservation Agents; Female | 2012 |